EP2026657A1 - Composition anticancéreuse et sa méthode d'utilisation - Google Patents

Composition anticancéreuse et sa méthode d'utilisation

Info

Publication number
EP2026657A1
EP2026657A1 EP07784125A EP07784125A EP2026657A1 EP 2026657 A1 EP2026657 A1 EP 2026657A1 EP 07784125 A EP07784125 A EP 07784125A EP 07784125 A EP07784125 A EP 07784125A EP 2026657 A1 EP2026657 A1 EP 2026657A1
Authority
EP
European Patent Office
Prior art keywords
composition
cesium
tumor
cancer
ion source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07784125A
Other languages
German (de)
English (en)
Other versions
EP2026657A4 (fr
Inventor
Brian C Giles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaionix Inc
Original Assignee
Pharmaionix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaionix Inc filed Critical Pharmaionix Inc
Publication of EP2026657A1 publication Critical patent/EP2026657A1/fr
Publication of EP2026657A4 publication Critical patent/EP2026657A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Definitions

  • This invention is in the field of pharmacology, and relates to anti-neoplastic drugs that include cesium and or rubidium salts for treating cancerous tumors, which are useful as stand alone anti-cancer therapies or as adjunct for radiosensitizing and/or chemosensitizing agents and cancer therapies and procedures in general. More particularly, the present invention is directed to an anti-cancer composition for topical administration which includes a source of cesium ions, a source of rubidium ions, or both.
  • Drug resistance can result in the ineffectiveness of antineoplastic drugs.
  • An example of a mechanism of drug resistance is the expression of the MDRl gene, which encodes a glycoprotein which acts as an energy dependent multidrug efflux pump in the plasma membrane.
  • Chemosensitizer efficacy depends primarily upon its ability to enhance the cytotoxicity of a chemotherapeutic drug and also on its sufficiently low toxicity in vivo. Chemosensitization research has centered on agents that reverse or modulate the multi-drug resistance in solid tumors (MDRl, P-glycoprotein).
  • Chemosensitizers known to modulate P- glycoprotein function include: calcium channel blockers (verapamil), calmodulin inhibitors (trifluoperazine), indole alkaloids (reserpine), quinolines (quinine), lysosomotropic agents (chloroquine), steroids, (progesterone), triparanol analogs (tamoxifen), detergents (cremophor EL), and cyclic peptide antibiotics (cyclosporines).
  • chemosensitizers benefit only a portion of the patient population.
  • the failure of current chemosensitizers and radio-sensitizers to reverse clinical multidrug resistance may be due to a number of factors which include the following: i) dose levels of the chemosensitizing agent may be inadequate at the tumor site, ii) levels of P-glycoprotein may increase as the tumor progresses, iii) the MDRl gene may mutate, resulting in decreased binding of the chemosensitizing agent to P-glycoprotein, iv) alternative non-P- glycoprotein mechanisms of resistance may emerge during treatment that are unaffected by chemosensitizing agents and v) a general lack of tumor site affinity (tumor selectivity) for chemosensitizers and their sensitization of normal healthy tissues to the toxic effects of chemotherapy.
  • chemosensitizers may have drawbacks.
  • cardiovascular side effects associated with continuous, high-dose intravenous verpamil therapy are significant and dose-limiting
  • ii) dose-limiting toxicities of certain chemosensitizers, such as trifluoperazine and tamoxifen is attributable to the inherent toxicity of the chemosensitizer and not due to enhanced chemotherapy toxicity
  • iii) using high doses of cyclosporin A as a chemosensitizer produces hyperbilirubinemia as a side effect.
  • chemosensitizers and radio-sensitizers are increasingly needed in the physician's art to improve the treatment outcome of chemotherapy patients.
  • the present invention addresses these limitations and provides herein a potential new class of chemosensitizers and chemotherapies and radiosensitizers that permit new approaches and outcomes in cancer treatment.
  • skin cancers such as malignant melanoma and the non- melanoma skin cancers, particularly basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs).
  • BCCs basal cell carcinomas
  • SCCs squamous cell carcinomas
  • BCCs currently affect one in 1,000 in the U.K. population, and the incidence has more than doubled in the last 20 years.
  • One million new cases of BCCs and SCCs are expected to be diagnosed in the USA in 1997, compared to 600,000 in 1990 and 400,000 in 1980.
  • UVB ultraviolet radiation bands are responsible for burning the skin and are also associated with the propagation of malignant melanomas (depletion of the ozone layer of the stratosphere is generally considered to contribute to long-term increases in skin cancer) while UVA ultraviolet radiation bands are associated with premature skm aging and the development of
  • Surgical removal is by far the most common treatment for malignant melanomas, BCCs and SCCs This can take the form of electrodesiccation and curettage, cryosurgery, simple wide excision, micrographic surgery or laser therapy
  • Other treatments, used when the cancers are detected at an advanced stage of development, are external radiation therapy, chemotherapy, or to a lesser extent bio-immunotherapy or photodynamic therapy
  • the choice of therapies is dependent on the type and stage advancement of the disease and the age and health of the patient All of the p ⁇ or art therapies suffer from severe limitations P ⁇ or Art Treatment Modalities
  • Surgical cancer therapy relies on surgical intervention for the removal of the tumor load
  • the reported rates for incompletely-excised BCCs was about 30-67%
  • the immune suppression associated with surgery may also cause any remaining cancerous cells to proliferate, and increases the risk of metastases
  • surgery produces pain (acidosis), which requires a separate drug for its management that may contribute to chemical and psychological addiction
  • Chemotherapy relies primarily on differential toxicity and often does not reach the targeted tumor sites at the tumor edge It also carries a high risk of immune suppression 3 Radiation therapy's mode of action causes damage to rapidly growing cells
  • Radiotherapy uses ionizing radiation to control malignant cells It is occasionally used as a palliative treatment for symptomatic relief Total Body Irradiation (TBI) is prescribed for some types of cancer such as Leukemia.
  • TBI Total Body Irradiation
  • IGRT Image Guided Radiation Therapy
  • IGRT X-Ray Tube and a Si-detector mounted on a linear accelerator.
  • the patient is scanned and the tumor is located in 3D space. This procedure allows for smaller margins to be used thereby sparing more healthy tissue and escalating the tumor dose.
  • radiation therapy can still carry a high risk of immune suppression and poor tumor specificity.
  • Stem cell therapy involves the use of both autologous and (matched) heterologous bone marrow-derived cells for replacing the immune cell population in various types of leukemia and lymphoma. This procedure requires extreme safety measures and is highly stressful for patients. In addition, it is costly and is limited to only a restricted number of malignant diseases.
  • Immunotherapy employs several forms of immune cells isolated from patient's blood (e.g. dendritic cells, lymphokine activated killer cells) which, after in vitro stimulation with tumor antigens or immune modulators, are re introduced to the patient.
  • the intention of this therapy is to enhance the anti-tumor capacity of the immune system.
  • Another approach is to use in vitro incubation of cancer cells from a patient's tumor with natural or artificial immuno modulators (e.g. interferon gamma) in order to induce the expression of membrane molecules (histocompatibility antigens) that can activate those cells from the patient's immune system that are responsible for tumor surveillance and anti-tumor activity.
  • Membrane fragments of these activated cancer cells are re introduced into the patient with the aim to enhance anti-tumor efficacy of the individual's immune system.
  • Limitations of the immunotherapeutic approach include the limited number of tumor types that have successfully been treated (e.g. melanoma, kidney tumors), the expense and complexity of the procedure, and the limited success rates. 6.
  • Gene (Modulation) Therapy is still in its infancy. There are several options, ranging from insertion of specific gene sequences coding for proteins interfering with tumor cell survival (e.g. apoptosis induction, cell cycle arrest) to induction of increased expression of genes involved in the inhibition of angiogenesis by means of natural or artificial modulators of gene activation (no gene insertion). The major limitation to this approach is the difficulty in achieving the required systemic specificity and efficacy.
  • cancer therapies seek to destroy tumors through surgery, radiation or chemotherapy. These therapies are largely based on the following two paradigms: (1) cancer is 'alien' tissue and therefore must be removed or destroyed and (2) cancer cells proliferate faster than normal cells and therefore methods and compositions that act on rapidly proliferating cells should destroy cancer.
  • Current anti-cancer therapies in fact, almost always inflict further injury. If cancer is the result of transformation injury, further injury by the hostile physiological environment within the solid tumors or the hostile electrophysiological environment induced in supporting stromal tissue by practicing the current therapies may serve to exacerbate the original malignant phenotype.
  • the acidic pHe promotes persistent antigenic and metastic signaling, metastatic spread of cancer and neovascularization (including angiogenesis, enhancing blood flow to the tumor mass).
  • the acidic pHe also decreases the efficacy of the immune response to cancer cells.
  • cancers exhibiting the lowest pHe values are more acidic and more aggressive and hostile (invasive) to the surrounding normal healthy cells and more likely to be fatal to the patient.
  • metastasis is responsible for 90% of cancer deaths.
  • an acidic hypoxic micro- environment causes genomic instability, and increased resistance to conventional cancer treatment procedures such as multiple drugs, radiation, and chemotherapy.
  • cancer cells have a lower energy charge (ATP/(ADP + Pi)). Additionally, most varieties of cancer cells typically have cellular distributions of ions that are different from normal healthy cells. Neoplastic cancer cells usually contain excess internal sodium and grossly excess internal calcium, often with a deficiency in internal potassium.
  • the key to using aberrant energy metabolism as a way to enhance site affinity that specifically targets the cancerous tumor cells' microenvironment that produces measurable tumor selective alkalinization involves administering an alkaline composition that has little toxicity to normal healthy viable cells which preferentially targets and elevates the pH level of the tumor micro-environment, thus causing the non-viability and apoptosis of tumor cells. This leads to the elimination of tumors and metastases and the electro-physical environment forces the cancer cells to die.
  • the composition of the present invention reduces and eliminates the hypoxic acidification produced by the cancer cells so that the physiologic pHe range is modulated (elevated) and approaches a physiological optimum range between 7.31 to 7.45.
  • This elevation of the tumor microenvironment promotes the formation of an electro- physical barrier to resist pH reduction and provides resistance to tumor formation and proliferation and invasion, metastasis seeding, and localized neovascularization.
  • a therapy that takes into account the consequences of low pHe and pHi and that increases tumor pHe and tumor pHi without causing serious side effects provides significant improvements over the prior art.
  • the composition and method of the current invention is separate from and superior to the above-referenced prior arts by eliminating the short and long term toxic side effects so prevalent in the prior art methods and compositions.
  • An object and advantage of the present invention is to provide a therapeutic composition with tumor site affinity that selectively modulates (elevates) the tumor's micro- environmental (pHe), which typically ranges from 6.70 to 6.80, to a more physiologically optimum pHe range from about 7.31 to 7.45 or slightly higher to bring the tumor cells out of their viability zone such that they die in a predictable and controllable rate.
  • Another object of the present invention is to provide an anti-cancer composition and method that can be cost-effectively administered as a stand-alone topical chemotherapy or employed as an adjunct in conjunction with a wide variety of conventional cancer therapies.
  • a further object of the present invention is to provide a composition that can be employed as a topical chemosensitizer in reversing drug resistance by preferentially targeting and elevating the tumor micro-environment to enhance the electro-physical environment for therapeutic gain for a wide variety of tumor types.
  • the composition of the present invention acting as a chemosensitizer increases the effective values of chemotherapeutic drugs and can be used in both in vivo and in vitro applications.
  • Still another object of the present invention is to provide a topical treatment which can help prevent or treat metastatic tumors at the primary tumor site with enhanced site affinity for malignant cells that is not restricted by the type of cancer cell.
  • Yet another object of the present invention is to provide a rapid testing process and procedure ranging from about 24 to 48 hours to clinically verify the efficacy of the inventive composition in a patient suspected of or diagnosed with cancer and to verify the efficacy of the composition in an individual patient's particular cancer or cancers to determine the doses, times, and the regimens for favorable outcomes.
  • the cancer therapy and composition for using the same of the present invention involves administering a therapeutically effective and non-lethal amount of a pharmaceutical composition to mammals in need of such a therapy and more specifically humans suffering from cancerous neoplasms and to prevent the formation and elimination of the hostile cancer viability zone and more specifically the tumor micro-environment which can help treat metastatic tumors and at sites other than a primary tumor site with site specificity for malignant cells that is not restricted by the type of cancer cell, including damaged or necrotized cells and tissues.
  • "Inherent bio-localization" for targeted in vivo and vitro delivery means having specificity for targeted sites for damaged tissues.
  • the method and composition may be administered as a therapy to obtain complete remission.
  • the method employs administering a virtually nontoxic composition to electrophysically suppress and eliminate the formation of the electrophysiological viability zone of cancers.
  • the method and composition described in the invention have several related effects on the development and propagation of cancer's micro-environment.
  • the current inventive composition interferes with the hypoxic acidic dependent energy metabolism of the cancer cells. This effect renders the cancerous cells less able to supply the energy required for their rapid proliferation that is typical of cancerous tumors thereby resulting in the reduction or elimination in the viability zone of the cancer cells
  • the composition reduces localized acidification (preferentially in the tumor micro-environment) and increases oxygenation, eliminating the adverse effects caused by acidic hypoxia
  • One exemplary embodiment of the present invention is directed to an anti-cancer composition for topical administration which includes a cesium ion source and/or a rubidium ion source and a carrier suitable for topical application
  • the key advantage is delivering the composition m a lowered or suitable viscosity range so that it serves as a penetrating agent
  • a composition of the present invention having a viscosity at or below about 36 dynes per cm 2 will see
  • the composition may include a pH within a range of about 6 7 to 7 2
  • the earner may include a liquid, a gel, a cream, an ointment, a lotion, a paste, en emulsifier, a solvent, a liquid diluent, a powder, or any other medium suitable for topical application
  • the composition may include an ORP within a range of about -Im v to about -50m v
  • the inventive composition may also further include a surfactant or surfactants Skin Type For Topical Administration For Variable Skin Types
  • Another exemplary embodiment of the current invention encompasses a method and composition to be topically administered or applied to a patient having cancer with skin that is thin (or very thin) that is adjusted with a suitable surfactant for the corresponding penetration such that the composition has a viscosity ranging between about 15 to 25 dynes per cm 2 and a pH range of about 6 70 to 7 20
  • Yet another exemplary embodiment of the current invention encompasses a method and composition applied to a patient having cancer that has normal skin thickness that is correspondingly adjusted to penetrate with a suitable surfactant where the composition has a viscosity ranging between about 15 to 20 dynes per cm 2 and a corresponding pH range of about 6 70 to 7 20
  • Still another exemplary embodiment of the current invention encompasses a method and composition applied to a patient having cancer that has thick skm and/or very deep tumors that is adjusted with a surfactant such that the composition has a viscosity ranging between about 8 to 20 dynes per cm 2 and a pH range of about 6.70 to 7.20, more preferably ranging between about 10 to 15 dynes/cm 2 .
  • the composition may include cesium citrate as the cesium ion source with a concentration of 1/10 of one percent and the composition may be sufficiently adjusted to a near neutral pH with a viscosity of about 33 dynes/per cm or lower, ranging from 8 to 30 dynes per cm 2
  • Cesium and or rubidium ions alter the ionic physiology of the cancer cell, including inhibition of trans-membrane movement of potassium.
  • Cesium and rubidium are effective for the control of potassium fluxes and linked hydrogen ion (H+) and other fluxes that act on all acidic-dependent cancers and provide site affinity or site directing to selectively elevate the pH of the tumor micro-environment This provides a tumor selective modulation which elevates the tumor pHe and pHi to the physiological optimum range that is outside of the tumorous cancer's viability zone
  • the composition cesium and/or rubidium ions provide site directing ions for targeted in vivo delivery.
  • Bio-location or “Site-directing”
  • site-directed or “site affinity” means having specificity for targeted sites
  • Specificity for targeted sites means that upon contacting the cesium and rubidium ions with the targeted site, for example, under physiological conditions of ionic strength, homeodynamic balance, temperature, pH and the like, specific binding will occur The interaction may occur due to specific electrostatic, hydrophobic, entropic or other interaction of certain residues of the conjugate with the specific targeted tumor microenvironment residues to form a stable complex under conditions effective to promote the interaction.
  • the cesium ion source in the anti-cancer composition for topical administration includes a cesium salt selected from at least one of the following:
  • the cesium salts included in the composition of the present invention may be formed using a variety of acids, including, but not limited to- Carbonate, Chloride, Citrate, Malic, Malate, Nitrate, Phosphate, Sulfite, and Sulfate.
  • the carbonate, citrate and sulfate salts are safer than other salts and sulfate and citrate are the preferred forms Phosphate is relatively safe but may interact with calcium and the chloride form should be used with caution
  • the cesium salt may include a combination of cesium sulfate and cesium citrate in a ratio of about 3:2. An even more optimum ratio includes between about 2 to 3 cesium sulfate to about 1 cesium citrate.
  • the cesium ion source and/or rubidium ion source in the composition may comp ⁇ se a range of about 1 ,000 ppm to 150,000 ppm
  • the total combination of cesium salts preferably comprises from about 0 5% to 5% of the composition of the present invention
  • the inventive composition provides an enhanced electrophysical barrier to tumor growth, tumor invasion, metastasis seeding, and localized neovascularization for therapeutic gain for all stages of malignancies including some cancers that are resistant to conventional therapies
  • the composition bypasses the cancer cell's mechanisms of resistance against conventional anti-cancer drugs at dosages which are less toxic to normal healthy viable cells than the currently available anti-cancer drugs
  • the anti-cancer composition for topical administration may include a soothing agent such as a menthol, mentholyptus, or a eucalyptus and/or an electrolyte which includes one or more of sodium, potassium, calcium, chlorate, magnesium, bicarbonate, phosphate, and sulfate
  • the composition may also include at least one or more of Vitamin B6, Vitamin B12, Vitamin D2, Vitamin D3, manganese, an antibacterial, and antifungal agent, and an anti mold agent
  • the exemplary anti-cancer compositions of the present invention may also be used as adjuncts with one or more of the following a surgical procedure, a laser therapy, a micro- radiation pellet implant, a cryogenic procedure, a chemotherapy, a radiation therapy, a electrodessication/curettage, a laet ⁇ le therapy, an immuno-therapy, and an enzyme therapy
  • the present invention is also directed to a method for preventing or treating cancer which includes topically administering an anti-cancer composition for topical administration which includes a cesium ion source and/or a rubidium ion source, and a pharmaceutically acceptable carrier suitable for topical application
  • the method for treating cancer may also include the step of administering a cesium chelator and/or a rubidium chelator
  • the step of administering a cesium chelator and/or a rubidium chelator may include the step of administering one or more of omega 3 oil, cod liver oil, Vitamin E, and Vitamin A
  • the present invention also includes a method for treating a wound, a sore, a pain, an infection, an inflammation, a scar, or a dermatological condition which includes the topical administration of an anti-cancer composition which includes a cesium ion source and/or a rubidium ion source, and a pharmaceutically acceptable carrier suitable for topical application
  • the present invention is also directed to a composition for enhancing the toxicity of a topically administered chemotherapeutic agent which includes a cesium ion source and/or a rubidium ion source, and a pharmaceutically acceptable carrier suitable for topical application.
  • a topically administered chemotherapeutic agent which includes a cesium ion source and/or a rubidium ion source, and a pharmaceutically acceptable carrier suitable for topical application.
  • a therapeutic agent means conventional drugs and drug therapies, including vaccines, for treating cancer, viral infections, and other malignancies, which are known to those skilled in the art.
  • Radiotherapeutic agents are well known in the art.
  • complete remission or “remission” is defined as having normal blood pictures accompanied by no clinical manifestations of cancer and other immunological markers that are indicative of cancer.
  • viscosity is measured in dynes per cm2 at 20° Centigrade.
  • pHe is the pH on the exterior of the cell and pHi is the pH on the interior of the cell.
  • tumor micro-environment refers to both the non-cellular area within the tumor and the area directly outside the tumorous tissue but does not pertain to the intracellular compartment of the cancer cell itself.
  • "about” is defined as plus or minus 2.5%, unless specifically stated otherwise.
  • a method for treating cancer means that the disease and the symptoms associated with the cancer are alleviated, reduced, ameliorated, prevented, placed in a state of remission, or maintained in a state of remission.
  • pharmaceutically acceptable carrier includes any and all solvents, surfactant(s), dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.
  • cesium sulfate also means dicesium sulfate, sulfuric acid, and discesium salt.
  • cesium citrate also means 2-hydroxy-l,2,3-propanetricarboxylic acid salt.
  • glycerol also means glycenn, glyce ⁇ ne, propane- 1,2,3-t ⁇ ol, 1,2,3- propanet ⁇ ol, 1,2,3-t ⁇ hydroxypropoane, glyce ⁇ tol, and glycol alcohol It is a sugar alcohol that has three hydrophilic alcoholic hydroxyl groups (OH) that are responsible for its solubility in water Glycerol has a prochiral spatial arrangement if atoms and has a wide range of applications
  • DMSO also means dimethyl sulfoxide, methyl sulfoxide, and methylsulfinylmethane
  • the molecular formula for DMSO is C 2 H 6 OS Related compounds may also be used which include diethyl sulfoxide, dimethyl sulfoxide, dimethyl sulfone, and acetone
  • Normal healthy human cells optimally function in a pHe range between 7 31 to 7 45 and have a typical pHi ranging between 6 60 to 6 80
  • the common denominator for almost all solid cancerous tumors is that they require a reduced extracellular pHe (tumor microenvironment) which is more acidic than the intracellular pHi
  • Virtually all neoplasms have a narrow viability zone with a tumor microenvironment having a pHe ranging from about 5 50 to 7 21, and generally ranging from about 6 60 to 6 80 leading to an acid-outside plasma level pH gradient in the tumors
  • This acidotic outside pH gradient in tumors can exert a protective effect upon the cancerous cells particularly from weak acid- based anti-cancer drugs
  • the present invention is generally directed to a method for treating cancer and compositions for topical administration which include a cesium ion source and/or a rubidium ion source and a earner suitable for topical application
  • the anti-cancer method and compositions may be used therapeutically, as well as diagnostically, when coupled with, e g , radioactive agents, proton capture agents, or other tumor toxic physical or chemical agents These toxic substances are preferentially localized in the tumor microenvironment (as compared to their adjacent normal cells) through the specificity of attachment of the compounds
  • This site affinity or site directing (tumor selectivity) is universally recognized as a crucial factor for achieving effective anti-tumor therapy, and a factor which has currently not successfully been achieved
  • Cesium and/or rubidium ions have efficacy m site affinity which enhance their use as new therapeutic drugs and/or as adjuncts for other cancer therapies
  • the composition of the present invention is particularly useful in site directing
  • the low extracellular pHe is a consequence of tumor growth and is aggressively hostile to the growth and survival of normal viable cells. This low pH promotes rumor invasion and perfusion and further contributes to tumorigenic transformation, particularly where tissue had been subjected to mechanical trauma. This suggests a direct and possibly causative correlation between locally inadequate blood flow and localized acidosis and elevated tissue acidity, which in turn promotes cancer formation and a propagation environment.
  • Cesium and/or rubidium ions preferentially increase the alkaline ionic concentration in the tumor microenvironment, thus elevating tumor pHe to a more physiologically optimum range for fast tumor suppression and remission. Such a response is instrumental in reducing and eliminating tumor generated acidotic induced pain.
  • the composition of the present invention can alleviate, reduce, ameliorate, or place or maintain in a state of remission the clinical symptoms or diagnostic markers associated with cancer. A mixture of salts containing cesium ions is preferred.
  • the composition of the present invention promotes ionic changes in the pHe and pH by modulating cancer microenvironmental conditions that simultaneously enhance the ability of normal healthy viable cells and normal tissues surrounding the tumor to tolerate and resist decreased pHe and decreased pHi and to resist the transport of H+ efflux across cell membranes.
  • composition of the present invention promotes an electrophysical barrier to tumor invasion, eliminates the cancer viability zone (formation and propagation environment) which are a prerequisite for tissue invasion and metastatic seeding, eliminates the aberrant energy metabolism necessary for the viability of cancer formation and survival, and interrupts the transition from non-invasive premalignant to invasive malignant morphology including the acquisition of angiogenesis, increased glucose utilization and increased lactic acid and /or carbonic acid production.
  • the method and compositions can be used to determine the efficacy of the anti-cancer therapy in a particular patient through testing and observations relating to ionic anti-cancer physiology. Clinical observation and diagnostic testing are used for adjustment of the non-lethal dosages. A large number of cancer deaths are due to secondary infections, pnma ⁇ ly from bacteria invasion If a patient's immune system is suppressed by acidosis, such as bacte ⁇ al- mduced or tumor-generated acidosis, then the compositions of the present invention desc ⁇ bed herein will contribute to enhancing the functioning of the immune system and will promote resistance to secondary infections including helping the immune system fight the cancer
  • composition of the present invention suppresses a wide variety of infectious microorganisms, i e bacteria, which often have acidotic energy metabolisms This is advantageous in that antibodies and phagocytes cannot work effectively in tissue having increased acidity, i e a reduced pH
  • the composition(s) of the present invention are able to inhibit the growth of at least one cell line selected from the group consisting of, but not limited to the following MM96L, MM229, MM220, MM237, MM2058, B16, LIM1215, HeLa, A549, MCF7, MCC 16 and Colo 16 More preferably, the compound(s) is able to inhibit growth of, or to induce differentiation in, MM96L cells
  • the invention provides a composition comp ⁇ sing an active compound as desc ⁇ bed herein, together with a pharmaceutically-suitable earner or surfactants(s)
  • the composition and method of the present invention may be applied to a cancer which comp ⁇ ses a solid tumor
  • the method and composition of the present invention are particularly effective against cancers selected from the group consisting of malignant melanoma, other skm cancers including Merkel cell carcinoma, squamous cell carcinoma and basal cell carcinoma Additionally, the invention provides a method of inhibiting proliferative activity
  • the cesium salts included in the composition of the present invention may be manufactured using a wide variety of acids, and may include, but are not limited to, one or more of the following
  • the cesium salts included in the composition of the present invention may be formed using a variety of acids, including, but not limited to Carbonate, Chloride, Citrate, Malic, Malate, Nitrate, Phosphate, Sulfite, and Sulfate
  • the carbonate, citrate and sulfate salts are safer than the other salts and sulfate and citrate are the preferred forms Phosphate is relatively safe but may interact with calcium and the chloride form should be used with caution
  • the cesium salts which include carbonate, chloride, citrate and sulfate are generally safer.
  • Cesium phosphate is relatively safe but may interact with calcium.
  • Cesium chloride may mask cell differentiation (separating cancer cells from healthy cells). In addition, excessive doses of cesium chloride combined with exposure to light may promote a caustic effect to healthy skin
  • Cesium citrate is the preferred form of cesium salt for use in the topical composition of the present invention. Cesium citrate alone may have significant anti-cancer application.
  • Cesium sulfate has long term benefits in maintaining remission and produces minimum damage to healthy cells and tissues. Cesium carbonate provides a slightly more neutral range in combination with the cesium sulfate.
  • a preferred combination of cesium salts for use with the composition of the present invention includes a combination of two cesium salts, namely cesium sulfate and cesium citrate in a ratio of about 3 cesium sulfate to about 2 cesium citrate.
  • An optimum ratio of cesium sulfate to cesium citrate includes a ratio of between about 2 to 3 cesium sulfate to about 1 cesium citrate.
  • the inventive composition acts on a mucous level and a pH level, and/or a genetic level, and also provides the effective resonance for the optimum vibration level of anti cancer cell activity. Care should be taken in determining dosage because excessive dosage of the topical composition of the present invention can be detrimental in terms of the free radicals that are produced. Excessive doses that build up cesium in the lymph and incorrect cesium salt ratios should be avoided.
  • cesium and rubidium salts might be used in a wide variety of topical compositions, such as, but not limited to, various organic or metallic salts, if they meet the following requirements: (1) they must be pharmaceutically acceptable and have an acceptably low level of toxicity; and (2) they must have sufficiently high levels of cationic dissociation to allow the remaining negatively charged ions to effectively reduce acidity, including the acidity of tumor cells and skin lesions.
  • Another exemplary embodiment of the present invention includes a composition having cesium and/or rubidium ions in addition to ingredients that enhance ionic pH physiology.
  • ingredients include electrolytes (saline compounds) such as potassium, sodium, and magnesium. Potassium, and other major electrolytes (e.g. sodium, calcium, chloride, bicarbonate, phosphate, and sulfates) are preferably added to the formulation in proportion to the potassium.
  • electrolytes saline compounds
  • Potassium, and other major electrolytes e.g. sodium, calcium, chloride, bicarbonate, phosphate, and sulfates
  • Other ingredients that may be included to effectively potentiate the tumor site affinity for cesium/rubidium ionic action include manganese, Vitamin B6 (pyrodoxine), Vitamin D2, Vitamin D3, and/or Vitamin B12 Surfactants
  • surfactants can be used as penetrating agents, dispersing agents, solubihzing agents and spreading agents
  • Suitable surfactants for the present invention which act as penetrative agents are those which are reasonably stable throughout a wide pH range, including non-and amphoteric organic or synthetic detergents
  • Non-petrochemical surfactants are preferred
  • suitable surfactants include, but are not limited to polysorbates such as Tween 40 and Tween 80 (Hercules), sorbitan stearates, sorbitan mono-oleate, etc , sarcosinates such as sodium cocoylsarcosmate, sodium lauroyl sarcosmate (Hamposyl-95 ex W R Grace), canonic surfactants such as cetyl py ⁇ dinium chlo ⁇ de, cetyl t ⁇ methyl ammonium bromide, di-isobutyl phenoxy ethoxy ethyldiniethyl benzyl ammonium chloride and coconut al
  • surfactants include, but are not limited to, alkyl sulphates, condensation products, fatty alcohols, fatty amides, polyhyd ⁇ c alcohols (e g sorbitan monostearate, sorbitan oleate), PEG (polyethylene glycol) 400, Sodium lauryl sulfate, sorbitan laurate, sorbita pahtate, sorbitan stearate available under the tradename Spans RTM (20-40-60 etc ), polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tweens RTM (polysorbates, 20-40-60 etc), and Benzalkomum chloride
  • the preferred surfactant(s) are glyce ⁇ ne and DMSO DMSO is added
  • surfactants in the preferred composition of the present invention is to adjust the surface tension in dynes per cm ⁇ (at 20° C) of the compositions so that they can function as penetrating agents in order to maximize the amount of cesium and / or rubidium ions deposited in or near the nucleus of the cancerous cell i e tumor(s)
  • the surface tension of the solution is between about 8 to 50 dynes/cm, in order to yield a penetrating agent and /or carrier composition having a preferred surfactant within the range from about 8 to 36 dynes per cm ⁇
  • a topical composition has minimal systemic side effects
  • Surface tension of a given formulation may be adjusted by adding a surfactant(s) in addition to the active ingredients in order to bring it into the preferred range(s)
  • the HLB hydrophille-lipophile-balance
  • This arbitrary system consists of a scale to which HLB values are determined experimentally and assigned.
  • HLB value is low, the number of hydrophilic groups on the surfactant is small, which means it is more lipophilic (oil soluble).
  • Surfactants can act as a solubilizing agent by forming micelles.
  • a surfactant with a high HLB would be used to increase the solubility of an oil in a medium.
  • the volume of dilution fluid will vary according to the total dose administered and the required dynes per cm range.
  • formulations according to the present invention will preferably have a pH in the range of about 6.60 to 8.00; an osmotic pressure of the solution between about 100 m ⁇ sm/kg to 700 m ⁇ sm/kg; and a NaCl equivalency to the solution is preferably between about 0.5% NaCl to 4.0% NaCl.
  • the surface tension of the composition for topical administration with surfactants to between 8 to 50 dynes/cm ⁇ , more preferably between about 10 to 30 dynes/cm ⁇ , and most preferably between about 15 to 25 dynes/cm ⁇ .
  • compositions for this purpose may be formulated by using surfactants, NaCl or other chemicals entities to adjust the solution for administration to have the following properties: i) surface tension preferably between about 8 to 50 dynes/cm ⁇ , more preferably between about 10 to 30 dynes/cm ⁇ , and most preferably between about 15 to 25 dynes/cm ⁇ , ⁇ ) osmotic pressure between about 350 m ⁇ sm/kg to 800 mOsm/kg, more preferably between about 450 m ⁇ sm/kg to 700 m ⁇ sm/kg and most preferably between about 450 m ⁇ sm/kg to 600 m ⁇ sm/kg, and iii) pH preferably between about 6.60 and 8.00, but it may vary according to the properties of the medication used.
  • the surface tension and, to a lesser degree, the salt ratios are critical factors in getting optimal deposition of the composition into tumors in the skin. Having a surface tension that is too low increases permeation into and past tumor cells and into the circulatory system. This should be avoided. In contrast, if the surface tension is too high, much of the medication is not deposited within the tumors.
  • Glycerin may be both a surfactant and a carrier in the composition of the present invention.
  • Secondary ingredients are chosen to complement or potentiate the action of the cesium and or rubidium ions.
  • the examples of enhancing secondary ingredients are given to instruct the physician in the principals of their selection and are not intended to exclude other ingredients not mentioned or as needed by a specific patient
  • Enhancement of cesium and/or rubidium therapy can be accomplished by inclusion of ingredients that enhance the shift (elevate) towards apoptosis induced by ionic physiology
  • ingredients that enhance the shift (elevate) towards apoptosis induced by ionic physiology examples are compounds that stimulate calcium accumulation, such as calcium supplements with potassium and magnesium, preferably in a 2 to 1 ratio, preferably with an equal portion of Vitamin D3 combined with Vitamin D2, such as but not limited to calcium, with potassium and magnesium preferably administered somewhat independently or alternatively in a ratio of 2X or 4X as much potassium as magnesium if necessary, and 2X as much as magnesium as calcium, and 4X as much calcium as the potassium, and a small amount of manganese
  • Administering excessive doses of potassium should be avoided as it may cause arrhythmic responses in the heart of some sensitive patients In addition, administering excessive doses of calcium should also be avoided
  • Another class of ingredients which potentiate the activity of the cesium and rubidium ions are those which stimulate or support the immune system and normal healthy viable cells, especially those which may be deficient as a secondary consequence of cancer These include potassium, magnesium, manganes ⁇ i Vitamin D2, Vitamin D3, Vitamin B6
  • the composition should be administered sequentially with calcium, potassium, magnesium, or manganese
  • the inventive composition may be combined with systemic administration therapy or other routes or as a stand alone anti-tumor therapy chemosensitizer or as an adjunct with radiation therapy as a radiosensitizer
  • Cesium seeks to find its counter-ions to form salts In the process it nullifies some of the DNA and RNA disruption factors that take place in a variety of cancers Cesium forms less optimum structures in the cancers and destabilizes the cancerous tissues i e neoplasms and solid tumors
  • each ingredient is weighed/measured out individually, added together and dissolved in a sterile glycerin and DMSO composition for administration The preparation is then tested to ensure that it is within the parameters established for surface tension, osmola ⁇ ty, pH, and sodium chloride equivalency This is done by using the approp ⁇ ate equipment for each test To prepare a unit dose, the ingredients of such formulations generally will be dissolved in a solvent such as glycerin and DMSO or other suitable solutions
  • the pH of the va ⁇ ous solutions may need to be adjusted to achieve stability or increase effectiveness
  • the pH is adjusted by adding buffe ⁇ ng agents to arrive at the most preferable range of pH needed for a particular tumor or skin type
  • the surface tension may also be adjusted using surfactant(s) to fall within a preferred range in dynes/cm 2
  • the topical composition of the present invention is light sensitive Modes of Administration
  • compositions may take the form of gels, oils, creams, ointments, bandages, impregnated plastic strips, patches, transdermal patches, dressings, gauze, topical lotions, transdermal patches, etc
  • compositions may also be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials INCLUSION CRITERIA
  • Inclusion criteria for the method and composition of the present invention include 1 ) patients who show verifiable tumor control or shrinkage withm 24 to 48 hours after administration of the initial testing dosage of the inventive composition, 2) patients who are unable to attain complete remission with cytotoxic agents, and 3) patients in complete remission after conventional treatment who show residual cancer cells, indicating likelihood of relapse
  • the method and topical composition of the present invention encompasses a testing procedure for testing patients with suspected or diagnosed cancer with the method and composition It also includes determining the therapeutic gain for tumor control and remission m an individual patient with a particular variety of cancer or cancers and stage of advancement to actually help determine the predictable outcomes of using the current inventive methods and compositions in an individual patient including doses, routes, durations and resting pe ⁇ ods
  • testing can be performed to measure the efficacy of the composition (tumor sh ⁇ nkage) after administration of the composition to the patient between 24 to 48 hours, more preferably testing is performed between 24 to 48 hours after the initial administration of the composition EFFICACY
  • the method and composition of the present invention can be used alone or in combination to act as a sensitizer for chemotherapeutics, radioprotectants, radiotherapeutics, and radiosensitizers to either improve the quality of life of the patient, or to treat cancer
  • the inventive topical composition can be used as an adjunct administered before, du ⁇ ng or after the administration of one or more known antitumor agents (See, for example, the Physician Desk References 1997)
  • the inventive topical composition can be used before, du ⁇ ng or after a wide variety of radiation treatments Sequential administration is preferred TOPICAL THERAPY AND PROTOCOL
  • the inventive topical composition of the present invention provides a method and composition for preventing or alleviating damage to skm, which includes, but is not limited to, damage caused by ultraviolet irradiation, ionizing radiation, exposure to ozone, microwave radiation, or the like
  • the method comprises the step of topically administering an effective amount of a compound of the present invention to a subject in need of such treatment This aspect of the invention may be used
  • the invention provides a method of stimulating proliferation of non-neoplastic cells which comprises the step of exposing the cells to a proliferation-inducing amount of a compound or a composition of the current invention. This is useful m inducing regeneration of cells and tissues and, because T-lymphocytes may proliferate in response to the compositions of the invention, it is useful in promoting the immune response to disease states.
  • the compounds of the invention are suitable for use in medical treatment of humans, it is also applicable to veterinary treatment, including treatment of companion animals such as, but not limited to, dogs and cats, and domestic animals such as horses, cattle and sheep, or zoo animals such as felids, canids, bovids, and ungulates. Dosage is at the discretion of the attendant physician or veterinarian, and will depend on the nature and state of the condition to be treated, the age and general state of health of the subject to be treated, the route of administration, and any previous treatment which may have been administered.
  • the present invention is effective in ameliorating damage from solar UV and like agents by enhancing DNA repair and the immune response either in the target or effector cells.
  • the compounds of this invention are expected to have activity in modulating gene expression in the G-protein, PKC and Ras signaling pathways in a manner that leads to anticancer activity in vivo.
  • the present invention also has use as an adjuvant to radiotherapy or to therapy with other DNA- damaging agents on the basis of down-regulation of protective proteins (GADD45 and DAP3).
  • the administered dosages of the inventive composition depend on the type of the rumor and its location in the dermal layers of the body, the volume and mass of the tumor, and the therapeutic effects on the tumor from the composition.
  • the topical composition of the present invention is preferably in a low or suitable viscosity range. For example, a composition having a viscosity at or below about 36 dynes per cm 2 will seep in between the cells and is transferred osmotically from cell to cell thereby enabling the composition to penetrate into the subcutaneous tissues.
  • the viscosity transition range between the inside of the cell to the outside of the cell is about 36 dynes per cm 2 depending upon the cell hydration and other factors.
  • the preferred composition's viscosity range for topical application is below 36 dynes per cm 2 .
  • the composition preferably consists of a combination of two cesium salts, namely cesium sulfate and cesium citrate in a preferred ratio of about 3 cesium sulfate to 2 cesium citrate.
  • a more optimal ratio may include about 2 to 3 cesium sulfate to about 1 cesium citrate.
  • Cesium sulfate salt promotes less free radical damage to the cell tissues, is more neutral to the normal healthy cells, is detrimental to the cancer cells, and further contributes to the cell differentiation between the two types of cells. Cesium sulfate is also more effective in terms of safety for longer term administration and for maintaining a state of complete remission.
  • the physician should administer a topical dose of the composition of the present invention sufficient for a balanced reaction on a molecular basis and should avoid excessive doses that permeate past the needed area. For example, a practical calculation would be no more than one cesium and / or rubidium ion per cancer cell.
  • the physician should also avoid administering the composition into a lesion for a prolonged period (i.e. over a period of 1 to 2 consecutive days). After the predetermined time period for administration, the physician should remove any of the topical composition from the affected area.
  • An exemplary embodiment of the invention encompasses the treatment schedule and timing of the administration of the topical composition, including an administration period, a resting period, and a testing period on cancerous, precancerous moles and/or precancerous lesions.
  • the physician should first ascertain whether or not the suspect site is precancerous or cancerous using the standardized indicators for skin cancer. Once the physician has identified those cells that have become pre-cancerous or cancerous cells, a single topical administration of the composition of the present invention should be administered to the affected area. Remission is generally obtained within 10 to 12 days and usually about 3 to 6 days.
  • the composition is fast acting and long lasting and has substantial cosmetic benefits for the patient, particularly for the skin on a patient's nose and ears.
  • composition of the present invention may be re-administered after 6 to 8 days.
  • the majority of patients will complete the course of the topical therapy treatment within 3 to 6 days.
  • Bio-markers will show tumor suppression efficacy on an individual patient within the first 48 hours following the initial topical administration.
  • the topical compositions of the present invention include cesium and/or rubidium ions, preferably in an amount sufficient to provide from about 5,000 ppm to about 100,000 ppm, and more preferably about 10,000 ppm to about 50,000 ppm.
  • cesium salts are preferred as the source of cesium ions.
  • the topical composition of the present invention may also include a soothing agent or agents such as menthol or mentholyptus compositions.
  • the composition of the present invention may also include Vitamin B6 (pyridoxine) and/or Vitamin B 12 with a surfactant or surfactants.
  • the non-cesium/rubidium components must be non-bonding with the cesium and/or rubidium ion.
  • the optimum pH for the skin without causing irritation is about 7.10.
  • the pH of the inventive composition should range between 6.70 and 7.10.
  • the composition of the present invention has a preferred pH range of about 6.70 to 6.80 for patients with very thin or fragile skin, and in particular for patients of advanced age. Even a slight pH change in some sensitive patients can irritate their skin. The patient should not expose the affected area or areas to sunlight during the therapy cycle.
  • the preferred viscosity range of the topical composition is between about 15 to 25 dynes per cm 2 .
  • the surface tension is adjusted such that the composition of the present invention penetrates through and just a little below the first three dermal layers, thus producing minimal leakage of the cesium ions thereby eliminating damage to the surrounding healthy, viable cells.
  • the viscosity of the inventive composition is preferably adjusted to sufficiently penetrate through the first and, if necessary, the third layer of skin, to the subdermal tissues and into the cancerous tumors, but not excessively deep so as to penetrate the underlying vasculated tissue.
  • the composition may comprise a small amount of Dimethyl Sulfoxide (DMSO), ranging between 0.20% to about 1.50%, preferably about 0.75% with a maximum of about 5.0%, for adjusting the viscosity to a range that promotes the transport of the salts comprising cesium and/or rubidium ions into or between the cancerous cells.
  • chelation therapy may be administered in conjunction with administration of the inventive composition. Patients who previously received cesium or rubidium therapy, sensitive patients (e.g. advanced age) who have previously been administered multiple cesium and/or rubidium topical therapies, and patients who have received excessive doses (such as oral, injection or other routes of delivery) of the inventive composition over a short period of time may all be candidates for chelation therapy
  • a formula containing cesium chloride in olive oil was topically administered for 8 consecutive days to a 62-year-old male having a large suspect mole on his back approximately 18 mm by 35 mm The mole was completely removed in about 10 days, and the underlying skin looked healthier and younger than the surrounding skin TOPICAL PROTOCOL - EXAMPLE 2
  • a formula containing cesium chlonde with water was topically administered for 7 consecutive days to a 56-year-old male having a large suspect flat mole on his scalp approximately 10 mm by 12 mm The mole was completely removed m about 10 days, and the underlying skm looked healthier and younger than the surrounding skin TOPICAL PROTOCOL - EXAMPLE 3
  • a formula containing rubidium carbonate in sesame oil was topically administered for 7 consecutive days to a 63-year-old male having 6 suspect round moles on his neck approximately 4 to 5 mm in diameter The moles were completely removed in about 8 days TOPICAL WASH/RINSE
  • the topical composition may be administered as a wash or rinse to suppress tumor growth after surgical procedures, to obtain remission, or to suppress secondary effect of bacte ⁇ alogical invasion
  • the surface tension of the inventive composition when used m the form of a wash or rmse is may be adjusted using a surfactant ranging between 8 to 40 dynes per cm 2 , and more preferably a surfactant ranging from 15 to 25 dynes per cm 2 PROMOTE HEALING CYCLE
  • compositions of the present invention encompass stimulating the healmg process of any wound(s) contaminated with microorganisms
  • the compositions of the present invention function specifically to maintain the necessary antibacterial environment for wounds to heal faster, without the usual complications associated with superficial infections
  • the solutions provide pam suppression and less scarring WOUND CARE
  • the method and composition encompasses preventing and suppressing a broad spectrum of microbial growth (anti- microbial) and reducing inflammation m the targeted zone, thereby promoting faster wound healing, especially in the area of more efficient delivery of the therapeutic agent to the wound care site and/or tumor site, particularly in the topical application to wounds, burns, etc
  • Cesium salts are preferred
  • the topical application most prefe ⁇ ed is the combination of cesium sulfate and cesium citrate
  • This exemplary embodiment of the present invention encompasses administering the inventive composition in the form of a treated bandage or gauze for a wide variety of wound treatments
  • An exemplary embodiment of the current invention encompasses a method of using the inventive composition as an adjunct to other topical treatments, including, but not limited to, bandages that may be used in combination with the composition or with other compositions or topically applied materials for improvements in wound care management using a combination or mixture of cesium and/or rubidium salts and / or a specific combination of cesium and/or rubidium salts with improved anti-microbial and antiinflammatory compositions and wound dressings
  • the cesium and/or rubidium salts preferably comprise a mixture of cesium sulfate and cesium citrate
  • the inventive composition may be topically administered with a pH ranging between 6 50 to 7 20, more preferably between about 6 70 to 7 10, and with an ORP ranging between -1 m v to -50 m v , more preferably about -20 to -25 m v
  • a suitable dose of the composition is administered to affect the injured sites and cells in order to establish an electro-minus charge This promotes the electrical flow and simultaneously reduces scarring and pain while suppressing infection
  • composition suppresses infections that occur during surgery and shortens recovery periods and promotes the healing cycle of the normal, healthy, viable cells
  • the residual tumor cells will encounter a more hostile environment (more alkaline pHe) and, as a consequence, they are rendered nonviable and are eliminated
  • the invention also relates to a method of treating burns and wounds and the use of the subject compounds as antimicrobial agents
  • Antimicrobial properties of the composition include, but are not limited to, preventing growth of Escherichia coh, Listeria monocytogenes, Staphylococcus aureus, methicilhn-resistant S aureus (MRSA), Pseudomonas aeruginosa, Lactobacillus, yeast, vancomycin-resistant enterococcus, molds, and spores
  • the compositions of the invention may be osmotically balanced and of minimal cytotoxicity
  • a method and composition contains a formula of cesium and/or rubidium salts and minerals, such as an electrolyte concentration in an isotonic state.
  • the solution's composition typically comprises halide salts of sodium, potassium, calcium, and other cations and most typically chloride, sodium, potassium, and magnesium in the solution.
  • the composition of the invention is atoxic and has antibacterial properties.
  • Another exemplary embodiment of the present invention includes a cesium and/or rubidium salt containing composition having cesium citrate adjusted to a near neutral pH with a concentration of 1/10 of one percent and a viscosity that is below 33 dynes/per cm 2 , more preferably ranging between 15 to 20 dynes per cm 2 .
  • composition is useful in any application in which antimicrobial properties are desirable.
  • applications include, without limitation, treatment of wounds, burns, and canker sores; irrigation; cleaning of tissue sites (e.g., pre- and post-operative); for dermatological applications, psoriasis; and numerous applications which are readily apparent to one skilled in the art.
  • a formula containing cesium chloride and olive oil was topically administered for 3 consecutive days to a 42-year-old male having a slow-healing wound on his shin approximately 5 to 6 mm in diameter. The wound healed in about 4 days, and the underlying skin looked pink and younger than the surrounding skin.
  • the composition may be incorporated into bandages as an anti-bacteriant to reduce the scar formation process.
  • the composition promotes the healing of the affected tissue from the inside of the tissue.
  • the undamaged normal healthy viable cells are protected by the osmotic shielding of the cells, and the damaged unshielded or partially unshielded cells disassociate and are metabolized thereby reducing the formation of scar tissue and bacteria infection.
  • the composition is particularly useful in topical applications.
  • the invention encompasses administering the composition as an adjunct with surgical procedures for reducing the amount of scar tissue formation during surgical procedures.
  • Scar tissue occurs when there is an incorporation of large quantities of damaged cells in the formation of tissues. This often occurs when the immune system is enveloped in the process of healing tissues by the infected cells at the site of tissue damage.
  • the cesium ions in the composition promote the production of less defective cells and thus less scarring, i.e. there are less defective or damaged cells to be enveloped and this enhances the tissues' healing process at the site of damage and potentially lessens the potential future transformation that is necessary for cancer reoccurrence.
  • the cesium ions in the composition also eliminate the electrophysical environment in the scar tissue that promotes metastasis.
  • the invention encompasses all pharmaceutically active species of cesium and/or rubidium salts and also encompasses hydrated versions, such as solution(s), hydrolyzed products or ionized products of these compounds. These compounds may contain different numbers of attached water molecules.
  • the invention includes any cesium and or rubidium salt or salts or compound(s), whether used alone or in combination with other compounds, that can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission the clinical symptoms or diagnostic markers associated with cancers.
  • the current invention may take the form of a composition and method used as an adjunct with a wide variety of procedures, such as, but not limited to, electrodesiccation and curettage, cryosurgery, simple wide excision, micrographic surgery or laser therapy.
  • the method and composition of the present invention may also be used sequentially with other treatments that are used when the cancers are detected at a later stage of development. These treatments include external radiation therapy, chemotherapy, and to a lesser extent bio-immunotherapy or photodynamic therapy. Sequential administration is preferred, i.e. the method and composition of the present invention is preferably administered sequentially after the other treatments.
  • the present invention encompasses using the method and composition of the present invention as an adjunct with laser therapy.
  • the method and composition of the present invention may be used as an adjunct with laser therapy to reduce the scarring and pain that occurs as a result of wounds and/or surgical procedures etc. and to simultaneously suppresses staff infections and to promote and stimulate the healing process.
  • RADIATION PELLETS The method and composition of the present invention may also be administered to a patient diagnosed with cancer such as, but not limited to, prostate and breast cancers, as an adjunct with implanted micro-radiation-pellets thereby providing a significant improvement over the prior art of radiation therapy alone.
  • the topical composition of the present invention may be simultaneously or sequentially administered. BIOPSY PROCEDURES
  • the method and composition of the present invention may also be used as part of the protocol for a biopsy procedure prior to, during, or after anti-cancer and/ or anti-metastasis therapy.
  • the topical composition of the present invention may be topically administered to a patient preceding the taking of a tissue sample biopsy to prevent the risk of promoting metastasis during the procedure(s).
  • the present invention encompasses using the method and topical composition of the present invention as an adjunct for cryogenic procedures for consolidating topical cancer remission.
  • the topical composition is administered to the affected area 2 to 5 minutes after cryogenic procedures (after the temperature returns to normal) and the affected area is then covered with a bandage.
  • the method and topical composition of the present invention may be used for the treatment and prevention of metastases and cancer recurrences after operations, radiotherapy and chemotherapy, in an effort to consolidate remission.
  • a chelation protocol may also be used as part of the treatment.
  • Vitamin E doses may be administered as a catalyst to a 70 kg male for 24 hours (with a maximum dose of about 20 i.u.) in addition to Omega 3 oils, and/or other fish oils that are suitable as bonding agents or for promoting bonding neutrality.
  • the maximum dose is 1 Ox the daily recommended dose ranging between 3X to 1OX the daily dose in sufficient quantities to promote and eliminate the toxins from the patient's system that are encountered from the chemistry poisons and or radiation poisons produced during the chemotherapy and radiation therapies.
  • the physician may administer the composition as an adjunct for chemotherapy.
  • the topical composition of the present invention may be administered sequentially between about 1 to 4 hours after the initial administration of the chemotherapeutic agent or agents (depending on the chemistry of chemotherapeutic agents and the variety of cancer) in order to provide a sufficient time interval for the chemotherapeutic agents to initiate and poison the cancer cells.
  • the inventive topical composition and the chelating composition block some of the harmful effects of the chemotherapy from the normal healthy viable cells thus promoting therapeutic gain and reducing a variety of side effects.
  • the present invention also encompasses administering the topical composition to a cancer patient to shorten the therapeutic regime of a chemotherapy treatment schedule and to potentially lower the patient's overall doses thereby reducing the systemic toxicity from the chemotherapeutic agent(s)
  • the topical composition of the present invention has the potential to elevate (amplify) the anti-cancer activity of the chemotherapy by up to about 30% DIRECT TUMOR INJECTION
  • the method and composition encompasses administration by direct injection into a tumor mass with a syringe or other suitable delivery method encompassing directly injecting into the tumor mass to improve or enhance site directing or targeting
  • the composition is pH balanced and acceptable for injection, encompassing a protocol that is followed by a resting pe ⁇ od, then clinically testing for verification of tumor shrinkage after about 24 to 48 hours time
  • the compositions includes cesium and / or rubidium salt in a solution having an adjusted surface tension ranging from about 8 to 15 dynes per cm , preferably ranging between 8 to 15 dynes per cm 2 , more preferably about 10 dynes per cm 2 and producing an O R P from - 1 m v to - 100 m v , and preferably between -10 m v to -70 m v
  • the direct injection is administered sequentially or simultaneously with vitamin B 12 It may also administered with nutrient support composition including, but not limited, one or more of Vitamin D2, Vitamin D3, Vitamin B6 with Omega 3 oils, Vitamin A, and other nutrient support and sequentially administering chelators Generally, the duration from direct injection into the tumor mass to promote complete remission is obtained withm 10 to 15 days from the initial tumor injection
  • nutrient support composition including, but not limited, one or more of Vitamin D2, Vitamin D3, Vitamin B6 with Omega 3 oils, Vitamin A, and other nutrient support and sequentially administering chelators
  • the duration from direct injection into the tumor mass to promote complete remission is obtained withm 10 to 15 days from the initial tumor injection
  • Surfactants may also be formulated with the inventive composition that are specifically tailored to the type or variety of cancer STOMATITIS AND MUCOSITIS
  • the invention also encompasses a method and composition for the treatment of stomatitis and / or mucositis with an oral rinse or wash The composition penetrates the cancer or
  • the present invention provides an ionic, pH manipulating composition and protocols for inhibiting acidotic activity (reduced pH) for prophylaxis of a wide variety of oral diseases including precancerous lesions and a variety of oral cancers
  • the method and composition are effective to minimize levels of pain and symptoms that occur m a reduced pH environment, particularly in the region of the mouth and throat RADIOTHERAPY AND CHEMOTHERAPY
  • the method and composition of the present invention encompasses a treatment of cancer using cesium and or rubidium as an adjunct with other anti- cancer agents.
  • Use of the method and composition of the present invention lessens the risk of causing cancer in a patient's normal healthy cells when radiation therapy is used to treat cancer cells, and reduces or eliminates the suppression of the immune response that often occurs in conventional cancer therapies.
  • the present invention encompasses, but is not limited to, the sequential or simultaneous administration of a cytotoxic chemical compound or compounds such as, e.g., a nitrosourea, cyclophosphamide, adriamycin, 5- fluorouracil , paclitaxel and its derivatives, cisplatin or other cancer treating agents in combination with the topical composition of the present invention.
  • a cytotoxic chemical compound or compounds such as, e.g., a nitrosourea, cyclophosphamide, adriamycin, 5- fluorouracil , paclitaxel and its derivatives, cisplatin or other cancer treating agents in combination with the topical composition of the present invention.
  • the cytotoxic composition may be administered by any suitable delivery route.
  • Administering the composition of the present invention as an adjunct with a variety of chemotherapeutic agents is useful in the treatment of neoplastic disease. It also enhances the tissues' healing process at the site of the damage and lessens the potential future transformation that is necessary for cancer reoccurrence. It also prevents a metastasis environment in scar tissues, and prevents cancer recurrences after operations, radiotherapy and chemotherapy.
  • the present invention provides a method of chemosensitization which includes administering a chemotherapeutic agent and a composition to a patient.
  • “Chemosensitization”, as used herein, means that the composition increases or enhances the cytotoxicity of a chemotherapeutic agent or agents compared to a level of cytotoxicity seen by that agent in the absence of the inventive composition. That is, the composition "sensitizes" a cancer cell to the effects of the chemotherapeutic agent, allowing the agent or agents to be more effective.
  • the composition is also known to have anti-cancer activity on its own.
  • compositions of the present invention may be used as stand alone therapies or in combination as an adjunct with other known therapeutic agents (including chemotherapeutics, radio-protectants and radio-therapeutics) or techniques to either improve the quality of life of the patient, or to treat cancer.
  • the cesium salt compounds can be used before, during or after the administration of one or more known antitumor agents including but not limited to a wide variety of mustard compounds. (See, for example, the Physician Desk References 1997).
  • the cesium and or rubidium salt compounds can be used after radiation treatments The composition shortens the therapeutic window for the radiation therapy
  • the novel composition is useful as chemo-sensitizers or radio-sensitizers in patients having cancer
  • the compounds or composition have utility in patients having cancer which are sensitive to radiation or chemotherapy
  • the composition is typically administered to patients after they are subjected to irradiation or chemotherapy administration
  • Cesium ions are alkaline chemotherapy agents that disrupt the DNA of cancer cells
  • One exemplary embodiment of the present invention encompasses administering the inventive composition to block the tumor cell's ability to repair themselves after damage by chemotherapy and/or radiation, thus promoting the enhancement of tumor necrosis from radiation or chemotherapy, particularly tumor response to weak base drugs
  • composition of the present invention enhances the uptake of the composition drugs into cancer cells
  • This chemistry usually includes weak acids or weak bases, is limited under conditions due to the acidic extracellular/interstitial environment and neutral to basic intracellular conditions and the tumor's micro-circulatory factors
  • the pH gradient of the cancer cells' microenvironment is elevated, thus enhancing the uptake of the chemotherapeutic agents particularly the weak acids or the weak bases in the target tumor cells
  • An exemplary embodiment of the present invention includes a method of treating cancer in a patient including the steps of administering to the subject a chemotherapeutic agent and then administering the composition containing cesium and or rubidium salts having radiosensitization properties
  • the composition is administered after ionizing radiation to the patient in proximity to the cancer Cesium and rubidium have radiation sensitization properties, such as, but not limited to, enhanced removal of toxins from ionizing radiation
  • Ionizing radiation includes, but is not limited to, x-rays, internal and external gamma emitting radioisotopes, and ionizing particles ADJUNCT FOR TOPICAL CHEMOTHERAPY
  • cesium and or rubidium may be used as an adjunct for topical chemosensitizers
  • the composition may be topically administered sequentially to a patient suspected or diagnosed with cancer
  • cesium and or rubidium is used to enhance the cytotoxicity of topically administered chemotherapeutic agents or as a stand alone chemotherapeutic agent
  • Chemosensitization using cesium and or rubidium refers to an enhancement of cytotoxicity on the part of a chemotherapeutic agent more preferably comprising a combination of cesium salts, such as sulfate and citrate
  • the method comprises the steps of i) assaying cytotoxicity of a candidate chemotherapeutic agent in the presence and in the absence of cesium and or rubidium, and ii) selecting a candidate chemotherapeutic agent as a chemotherapeutic agent for which cesium and or rubidium salt or salts is a chemosensitizer when the cytotoxicity of the candidate agent is greater in the presence of ces
  • This may be accomplished by the administration of the composition then waiting 12 to 48 hours, more preferably 24 to 48 hours, and then testing (evaluating) and verifying the tumor control (shrinkage) by methods know in the physicians' art
  • the same procedure may be employed for other routes for radiosensitizmg agents or chemosensitizing agents, or as a stand-alone chemotherapeutic, etc
  • the chemotherapeutic composition can be incorporated into topical creams, lotions, solutions, ointments, gels, and other dermatologic formulations for topical treatment of skin cancer.
  • the method of the present invention encompasses administrating the topical composition to a patient who is diagnosed or is suspected of having cancer, such as, but not limited to, squamous cell carcinoma, basal cell carcinoma, and cutaneous lymphoma, and for premahgnant lesions such as actinic keratoses, and lesions of the skin such as psoriasis, seborrheic keratoses, and discoid lupus erythematosus
  • the physician should topically apply the dermatologic formulation only to the affected areas.
  • the required duration of occlusion is variable, depending on the stage of advancement, such as, for example, the thickness of the cancerous lesions and the presence of thick scales, etc.
  • Cesium used as chemosensitizers or radiosensitizmg agents may be administered sequentially after administration of the chemotherapeutic agent or agents or after about 2 to 4 hours following administration of the radiotherapy.
  • the cesium containing composition is preferably used after 2 to 5 hours and more preferably after 2 to 3 hours following administration of the radiotherapy.
  • a time frame or treatment schedule for in vivo administration of the composition is about 2 to 5 hours after administration of the chemotherapeutic agent.
  • the physician should consider the patients' activities and the foods and food products the patient is ingesting including diet, the variety of cancer, stage of advancement and the total volume and mass of the cancer as well as how it is dist ⁇ aded in the body of the patient
  • the composition to be used in the method of the invention will be administered in a pharmaceutically effective amount
  • pharmaceutically effective it is meant that the dose which will provide an enhanced toxicity to radiotherapy, and a variety of chemotherapeutic agents
  • the specific dose will vary depending on the particular composition chosen, the dosing regimen to be followed, when the particular chemotherapeutic agent is administered, and the route of administration
  • the present example provides methods for selecting chemotherapeutic agents for which the composition is a chemosensitizer
  • the candidate chemotherapeutic agents are screened for enhanced activity in the presence of the composition (cesium and/or rubidium salts) using an m vitro cytotoxicity assay such as the MTT cytotoxicity test
  • the composition is considered a chemotherapeutic agent for which the inventive composition is a chemosensitizer
  • the drug resistance may be circumvented in a dose-dependent manner by simultaneous or sequential administration of the present composition such as cesium and/or rubidium
  • a MDRl -transgenic mouse model may also be used to test for those chemotherapeutic agents for which compositions of the present invention is a chemosensitizer m repressing drug resistance
  • compositions are typically long-lasting, such that the reduction or elimination in pain occurs quickly and for a substantial period of time
  • inventive composition containing cesium and/or rubidium salts may be administered as a topical chemotherapy to a patient diagnosed with such cancers CHEMOTHERAPY ADJUNCT
  • An exemplary embodiment of the present invention encompasses administering the composition as an adjunct with chemotherapy
  • the cesium amplifies the chemotherapy that a patient has received or is going to receive
  • the maximum dose regimes for the therapy should not exceed 60 days consisting of three 5-day regiments followed with a resting and testing pe ⁇ od of 15 days per each 5 days of consecutive administration
  • the composition may be administered as a stand-alone therapy or as an adjunct radiotherapy and chemotherapy preferably administered sequentially with a composition containing of Vitamin D2, VitaminD3, and B6 (pyrodoxme)
  • the method and composition encompasses administering a variety of cesium salt with doses ranging from between 1 ,200 mg to 2,500 mg per 24 hours for a 70 kg male sequentially with a composition containing vitamin D2 and D3 with dosage ranging between (0 33 to 4 00 mg/kg), co-admmistered with Vitamin B6 (py ⁇ doxme) with dosages ranging between 1 mg to 40 mg per 24 hours for a 70 kg male
  • the topical composition may contain a suitable surfactant to adjust the viscosity within the therapeutic range from about 40 dynes/cm 2 to 10 dynes per cm 2 more preferably ranging between 10 to 20 dynes/cm 2 to effectively penetrate the nucleus of the cancerous cells
  • the invention also encompasses the use of combination therapy to treat cancers, especially cancer
  • the composition When administered, the composition provides for antimicrobial activity This activity reduces or eliminates the acidotic environment that promotes pain and lesions and will quickly reduce or eliminate tumor-generated pain for extended periods of time WOUND CARE KIT
  • kits for carrying out the therapeutic regimens of the invention comprise in one or more containers therapeutically effective amounts of the composition in pharmaceutically acceptable form
  • the composition in a vial of a kit of the invention may be in the form of a solution, e g , in combination with sterile salme, or buffered solution, dextrose solution or other pharmaceutically acceptable ste ⁇ le fluid
  • the composition may be lyophilized or desiccated, in this instance, the kit optionally further comprises in a container a pharmaceutically acceptable composition, preferably ste ⁇ le, and/or a packaged alcohol pad Instructions are optionally included for topical administration of the composition by a physician REVERSE CATHETER
  • composition of the present invention by reverse catheter or other suitable method is also contemplated by the present invention
  • the method and composition of the present invention may be used to treat bladder and renal cancers having measurable tumor-selective alkalimzation
  • Use of the composition may enhance tumor response to weak base drugs with significant alkalimzation of u ⁇ ne in humans for enhancement of a variety of anti-cancer therapies for certain bladder and renal tumors that are treated using weak base drugs such as but not limited to, anthracyclme and vinca that enhanced therapeutic gam in a weak base environment
  • Cancer cells tend to have thinner cell membranes than normal, healthy cells This factor has been the foundation of numerous types of chemo- and radiation therapies, which operate on the principle that cancer cells tend to be more susceptible to death due to cell stress and damage than normal cells Medical research has not currently found a way to exploit the very different metabolic distinctions between cancer cells and healthy cells the fact that cancerous tumors tend to undergo anaerobic glycolysis and generate more acidity than normal, healthy cells This invention, rather than inflicting serious damage on all of the cells in the body in an effort to selectively target and kill cancer cells, provides a more benign approach to treating cancer particularly glycolysis dependent tumors or tumor that have tumor microenvironments regardless of tumor type
  • cancer cells derive a major proportion of their energy from glycolysis
  • Normal healthy cells utilize an oxidative metabolism in which only a small proportion of energy is de ⁇ ved from glycolysis
  • Cancerous neoplasms require an alteration of this energy production with a transition from non-invasive premahgnant to invasive malignant morphology, ranging from large benign tumors to necrotic cancers, including the acquisition of angiogenesis, increased glucose utilization (with increased lactic acid production) with localized tissue acidity and typical tumor morphologies
  • the increased lactic acid production of tumors causes the micro environment outside the tumor to become more acidic, leading to a reduced acidic pH
  • This acidic pH kills the normal tissue cells, which surrounds the tumor (note the normal viable cells require a mild alkaline pHe of about 7 31 or slightly higher to remain healthy and viable )
  • the tumor is surrounded by necroticised normal cells If insufficient alkalimzmg agents are available to the healthy tissue cells surrounding the tumor,
  • the values/ranges of pHe measured correlate with invasiveness and metastasis and this (acidic) sub optimal- physiological pHe makes tumor cell lines more metastatic.
  • Cancerous viability is dependent on an acidic micro-environment. This is due in part to their aberrant energy metabolism which produces lactic acid and carbonic acid and in part to incomplete vascularization, which causes insufficient oxygen supply (hypoxia).
  • Tumors tend to be both hypoxic and acidic. Chronically hypoxic tissues are going to be (i.e. are always) acidic, whereas transiently hypoxic tissues may be acidic. This is due to microcirculatory factors, the more central part of the tumor is hypoxic, the exterior is transiently hypoxic.
  • the common denominator for nearly all solid tumors (neoplasms) is an acidic pH at the tumor's edge. This tumor pHe referred to as the tumor-micro environment that has a pH that ranges from as low as 5.50 to up to about 7.20 with an optimum cancer viability pH ranging between about 6.60 to 6.85.
  • Cesium and/or rubidium ions selectively alkalinize tumors by site affinity increasing the buffering capacity of tumor interstitial fluid, with only minor pH elevation effects on the pHe of normal, healthy, viable cells and tissues.
  • Cesium ions in the present invention are separate and distinct from man-made isotopes of cesium and rubidium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode rapide et des compositions dont on a découvert qu'elles présentent une cytotoxicité sélective contre plusieurs lignées de cellules cancéreuses différentes, pour le traitement d'une multitude de néoplasmes cancéreux présentant des micro-environnements tumoraux par administration d'une composition chimiothérapeutique antitumorale comme traitement séparé ou comme traitement adjuvant d'une chimiothérapie et/ou d'une radiothérapie, cette composition présentant une affinité accrue pour le site tumoral et élevant de préférence le pH au niveau du site tumoral en vue de la suppression et de l'élimination du micro-environnement tumoral acide, ladite composition étant administrée sous forme de chimiosensibilisant et/ou de radiosensibilisant renforçant la suppression et la rémission tumorales et inhibant la métastase tumorale. L'invention concerne la régulation des mécanismes de la physiologie intracellulaire et extracellulaire par administration de sels alcalins destinés à moduler le pH et à restaurer et améliorer la physiologie ionique. Lesdites compositions sont utiles pour traiter efficacement les cancers, et notamment les mélanomes malins et les carcinomes à cellules squameuses (SCC), ce qui permet d'inhiber l'angiogenèse, de réduire la prolifération métastatique et de supprimer la douleur acidotique induite générée par la tumeur.
EP07784125A 2006-05-24 2007-05-24 Composition anticancéreuse et sa méthode d'utilisation Withdrawn EP2026657A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80808106P 2006-05-24 2006-05-24
US80998406P 2006-06-01 2006-06-01
US87985707P 2007-01-11 2007-01-11
PCT/US2007/069695 WO2007140280A1 (fr) 2006-05-24 2007-05-24 Composition anticancéreuse et sa méthode d'utilisation

Publications (2)

Publication Number Publication Date
EP2026657A1 true EP2026657A1 (fr) 2009-02-25
EP2026657A4 EP2026657A4 (fr) 2009-12-09

Family

ID=41278173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784125A Withdrawn EP2026657A4 (fr) 2006-05-24 2007-05-24 Composition anticancéreuse et sa méthode d'utilisation

Country Status (2)

Country Link
EP (1) EP2026657A4 (fr)
WO (1) WO2007140280A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008335083A1 (en) * 2007-12-11 2009-06-18 Stephen H. Monroe Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CN112351796A (zh) * 2017-12-21 2021-02-09 V·W·李 用于治疗肿瘤的组合物和方法
WO2019240706A2 (fr) * 2018-01-26 2019-12-19 Demir Caner Composé de dichloro-acétate de césium destiné à être utilisé dans le traitement du cancer
WO2019236358A1 (fr) 2018-06-05 2019-12-12 Peter Novak Composés de rubidium destinés à être utilisés dans le traitement du cancer
AU2019475409A1 (en) 2019-11-22 2022-06-09 Vector Vitale Ip Llc Method of preventing the development of melanoma
WO2021235506A1 (fr) * 2020-05-21 2021-11-25 国立大学法人大阪大学 Agent thérapeutique contre le cancer épithélial
CN113303476B (zh) * 2021-04-23 2022-10-04 中山大学 铷盐及铷盐溶液在制备延长寿命和/或抗衰老产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003189A1 (fr) * 1992-07-31 1994-02-17 John Lai Methodes utilisant des ions cesium therapeutiques
WO2001015745A1 (fr) * 1999-08-31 2001-03-08 Giles Brian C Procede et formule destines a la remission des tumeurs et a la suppression du cancer
KR20020025109A (ko) * 2002-01-28 2002-04-03 박동인 함초연고
US20050244344A1 (en) * 2004-04-12 2005-11-03 Brian Giles Compositions for oral hygiene and method for using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253323A1 (en) * 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
WO2006039504A2 (fr) * 2004-10-01 2006-04-13 Cell Ionix, Inc. Procede et formule s'appliquant a la stimulation, au ciblage, a la liberation, a la circulation et a la reagregation des cellules souches

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003189A1 (fr) * 1992-07-31 1994-02-17 John Lai Methodes utilisant des ions cesium therapeutiques
WO2001015745A1 (fr) * 1999-08-31 2001-03-08 Giles Brian C Procede et formule destines a la remission des tumeurs et a la suppression du cancer
KR20020025109A (ko) * 2002-01-28 2002-04-03 박동인 함초연고
US20050244344A1 (en) * 2004-04-12 2005-11-03 Brian Giles Compositions for oral hygiene and method for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007140280A1 *

Also Published As

Publication number Publication date
EP2026657A4 (fr) 2009-12-09
WO2007140280A1 (fr) 2007-12-06

Similar Documents

Publication Publication Date Title
RU2270003C2 (ru) Лекарственное средство для лечения солидных опухолей на основе паклитаксела, стабилизированного альбумином
Sheldon et al. Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug
US20210338570A1 (en) Radiation sensitizer or anti-cancer chemotherapy sensitizer
US20020037917A1 (en) Treatment of cancer using lipoic acid in combination with ascorbic acid
EP2026657A1 (fr) Composition anticancéreuse et sa méthode d'utilisation
JPH01146829A (ja) 超音波による腫瘍治療用生理作用増強剤
Overgaard Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue
EP0335966A1 (fr) Substances vaso-constrictrices combinees a des agents cytotoxiques
Rijkmans et al. Successful treatment of radiation cystitis with hyperbaric oxygen
EP2175849B1 (fr) Traitement de mélanome
CN110731954A (zh) 亚砜类化合物在预防胸腹部肿瘤放疗并发症中的用途
US20120040022A1 (en) Gallium compositions for the treatment of liver cancer and methods of use
Liu et al. Efficacy of multiple low-dose photodynamic TMPYP4 therapy on cervical cancer tumour growth in nude mice
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
US20080038376A1 (en) Anti-cancer composition and method for using the same
WO2015036463A1 (fr) Application topique de vinca-alcaloïdes dans le traitement de la kératose actinique
CN116726021A (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
US11318161B2 (en) Methods of treating basal cell carcinoma and glioblastoma
Racnik et al. Electrochemotherapy with bleomycin in the treatment of squamous cell carcinoma of the uropygial gland in a cockatiel (Nymphicus hollandicus)
RU2814946C1 (ru) Способ терапии колоректального рака в эксперименте in vivo
RU2697250C1 (ru) Способ фотодинамической терапии рака кожи
JP7376678B2 (ja) Ｍ１マクロファージを有効成分として含む癌細胞標的型薬物送達体及び光熱治療効果増進用組成物
JP7101105B2 (ja) 超音波増感剤
RU2358779C2 (ru) Способ фотодинамической терапии опухолей
JPS59222413A (ja) プソラレン誘導体含有薬剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20091109

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20091103BHEP

Ipc: A61P 31/00 20060101ALI20091103BHEP

Ipc: A61P 29/00 20060101ALI20091103BHEP

Ipc: A61P 17/02 20060101ALI20091103BHEP

Ipc: A61P 17/00 20060101ALI20091103BHEP

Ipc: A61K 45/06 20060101ALI20091103BHEP

Ipc: A61K 33/00 20060101AFI20091103BHEP

17Q First examination report despatched

Effective date: 20100212

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120811